Medical company Medtronic plc (NYSE:MDT) reported on Tuesday the receipt of the CE Mark approval for its radial artery access portfolio, including the Rist 079 Radial Access Guide Catheter and Rist Radial Access Selective Catheter for the cardiac interventional community.
According to the company, the Rist 079 Radial Access Guide Catheter is the first catheter specifically designed for the unique demands of accessing the neuro vasculature through the radial artery versus access through the transfemoral artery and 510(K) cleared by US FDA.
The company revealed the Rist 079 Radial Access Guide Catheter is indicated for the introduction of interventional devices into the peripheral, coronary and neuro vasculature.
In addition, the company's Rist Radial Access Selective Catheter is indicated for the introduction of interventional devices into the peripheral, coronary and neuro vasculature as well as to facilitate introduction of diagnostic agents in the neuro vasculature.
Concurrent with the CE mark, the company said its radial artery access portfolio is now available in the UK, Italy, Spain, Germany and France.
AstraZeneca invests USD300m to expand US manufacturing for cell therapy
Innovent Biologics announces CFO transition
Cardio Diagnostics appoints Dr Vimal Ramjee as Strategic Advisor
Acticor Biotech reports positive ACTIMIS clinical study results in Lancet Neurology Journal